Stay updated with breaking news from Stanley Plotkin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
America’s Frontline Doctors agree: murdered infants at the heart of vaccine research, The old Nazi program in new clothing, Farben, Nuremburg, Medical experimentation and murder are one branch of the poisonous tree, Pfizer
Middle-East Arab News and Opinion - Asharq Al-Awsat is the world’s premier pan-Arab daily newspaper, printed simultaneously each day on four continents in 14 cities
Global quest underway to speed Covid-19 vaccine trials Modified12:22 am - Scientists are working on a benchmark for Covid-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage. Researchers are trying to determine just what level of Covid-19 antibodies a vaccine must produce to provide protection against the illness. Regulators already use such benchmarks - known as correlates of protection - to evaluate flu vaccines without requiring large, lengthy clinical trials. "You could use it to predict...
Reuters Reuters 21 July, 2021, 2:10 pm Vials labelled "Moderna, Johnson & Johnson, Pfizer-BioNTech coronavirus disease (COVID-19) vaccine" are seen in this illustration picture taken May 2, 2021. REUTERS/Dado Ruvic CHICAGO, July 20 (Reuters) – Scientists are working on a benchmark for COVID-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage. Researchers are trying to determine just what level of COVID-19 antibodies a vaccine must produce to provide protection against the illness. Regulato...
Jul 21, 2021 CHICAGO – Scientists are working on a benchmark for COVID-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage. Researchers are trying to determine just what level of COVID-19 antibodies a vaccine must produce to provide protection against the illness. Regulators already use such benchmarks — known as correlates of protection — to evaluate flu vaccines without requiring large, lengthy clinical trials. “You could use it to predict efficacy from a vaccine, which wi...